Clinical Evaluation of Rasanjan in the management of Sthaulya (Obesity)

A0 个研究点目标入组 48 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with known history of Pathophysiologic /genetic syndromes associated with obesity (Cushingâ??s syndrome, turnerâ??s syndrome)
•2.Patients with known evidence of malignancy.
•3.Patients on prolonged medication with corticosteroids, antidepressants, anticholinergics etc or any other drugs that may have an influence on the outcome of the study.
•4.Patients with known history of major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, tuberculosis, Psycho- Neuro endocrine disorders etc)
•5.Patients who have a past history of atrial fibrillation, Acute coronary syndrome, Myocardial infarction, stroke or severe arrhythmia in the last 6 months.
•6.Patients with known history of serious hepatic and pulmonary disorders.
•7.Known cases of Alcoholics and drug abusers.
•8.Prior surgical therapy for obesity.
•9.H/o Hypersensitivity to any of the trial drugs or their ingredients.
•10.Pregnant or lactating women.
•11.Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous 6 months.
•12.Patients who have completed participation in any other clinical trial during the past six months.
•13.Any other condition which the principal investigator thinks may jeopardize the study.

发起方